Inotiv’s Post

Excited to engage in this webinar, as it directly relates to my research as a radiotherapy researcher. The discussion on custom model development in preclinical oncology promises insights into addressing the complexities of anti-cancer therapeutics development. Looking forward to exploring the innovative strategies outlined by Certis Oncology Solutions, Inc. #CustomModelDevelopment #PreclinicalOncology #ResearchAdvancements

Discover the leading companies driving innovations in bispecific antibodies with curated analytics by LARVOL CLIN. 🧬 Stay informed and ahead in the dynamic field of antibody therapeutics. Explore more here: https://bit.ly/4bFSDpD #BispecificAntibodies #LARVOLCLIN #BiotechLeaders #CancerData #Oncology

What’s New for RNAi in 2025? The 6th RNAi-Based Therapeutics Summit is back with a fresh lineup of expert speakers within the RNAi space, including Armatus Bio, Inc., Benitec Biopharma Inc., Novartis, PepGen, and more. They will help refresh your understanding and explore the latest innovations in delivery technologies designed for precise and targeted therapeutic applications. Explore the official agenda here: https://ter.li/xmgwc2 But that's not all. The 2025 agenda will take a closer look at exciting new data on extra-hepatic targets, including preeclampsia, breast cancer, and fibrodysplasia ossificans progressive. Stay ahead of the curve and download the official summit brochure here: https://ter.li/v4wie2 #RNAi #RNAiTherapeutics #RNAiMedicines #Therapeutics #Networking #RNAiConference

Did you know that biomarkers can help show the effects of your treatment on a tumor and a patient’s response to your compound? As one of many methods used for early signal detection in oncology drug development programs, biomarkers can play a crucial role in the success of your trial. Learn more about the advantages and uses of biomarkers in our white paper: https://ow.ly/z3TU50RARo2

What’s New for RNAi in 2025? The 6th RNAi-Based Therapeutics Summit is back with a fresh lineup of expert speakers within the RNAi space, including Armatus Bio, Inc., Benitec Biopharma Inc., Novartis, PepGen, and more. They will help refresh your understanding and explore the latest innovations in delivery technologies designed for precise and targeted therapeutic applications. Explore the official agenda here: https://ter.li/xmgwc2 But that's not all. The 2025 agenda will take a closer look at exciting new data on extra-hepatic targets, including preeclampsia, breast cancer, and fibrodysplasia ossificans progressive. Stay ahead of the curve and download the official summit brochure here: https://ter.li/v4wie2 #RNAi #RNAiTherapeutics #RNAiMedicines #Therapeutics #Networking #RNAiConference

Don't miss out on the opportunity to hear from siamak tabrizi, Senior Scientist at Immunitas Therapeutics, as he shares his expertise on ADC drugs and their role in advancing cancer therapy. Day 1 of the conference will feature a comprehensive discussion on the latest research, applications, and prospects in this exciting field. To register as a delegate: https://lnkd.in/d6hD8wmn To become a sponsor: https://lnkd.in/gCWB47jS #oncology #oncologyresearch #cancer #medicine #oncologia #ngioboston2024 #immunooncology #healthcare #therapy #pharmaceutical #conference #marketsandmarkets #bostonconference2024

How will #precisiononcology evolve in the upcoming year? Laksh Aithani, CEO of CHARM Therapeutics, shares his insights on the future of oncology in Scrip Asks' latest feature, "What Does 2024 Hold For Biopharma? Part 6: Therapeutic Area Advances." Laksh predicts significant advancements in precision oncology in 2024, particularly in the development of PRMT5 inhibitors for MTAP-deleted cancers, as well as the introduction of state-of-the-art ROS1 and ALK inhibitors in lung cancer treatments. Discover more about the predictions made by #biopharma leaders regarding the impact of #AI and innovative drug development strategies for 2024: https://lnkd.in/eNRMWRb8 #drugdevelopment #healthcareinnovation #CHARMTherapeutics

Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/g8XPQSsa #biotech #france #texas #oncology #artificialIntelligence

Marc-Henry PITTY, MD, CEO of Oregon Therapeutics, "To date, our first-in-class #metabolicinhibitor, XCE853, has exhibited robust preclinical efficacy in both in vitro and in vivo models across multiple #cancer types. Lantern’s (NASDAQ: LTRN) #RADR®AI platform will leverage the in vitro and in vivo data to potentially advance XCE853 development in a highly targeted manner and will help inform disease indications and #biomarker signatures that can aid in the design of future #clinicaltrials and in the pursuit of combination therapies with other approved cancer drugs. Our team is looking forward to efficiently selecting among the landscape of ideal development options and efficiently de-risking future clinical development decisions." https://lnkd.in/gabi_27S #biotech #france #texas #oncology #artificialIntelligence

The newest report from Clarivate is out. Download it now!